Skip to main content
. 2018 Jul 20;12(1):53–60. doi: 10.1093/ckj/sfy053

Table 3.

Fabry treated patients with and without colocalization

Variables Fabry treated with colocalization Fabry treated without colocalization P
(n = 11) (33%) (n = 22) (67%)
Age (years) 36 (20–88) 38.5 (18–76) NS
Gender, male [n(%)] 3 (27) 9 (41)
eGFR (CKD-EPI) (mL/min/1.73 m2) 101.6 (40.7–119) 104.2 (18.2–156) NS
UPCR (g/g) 0.07 (0.04–0.34) 0.10 (0.05–2.45) 0.04
Podocyturia/creatininuria (cells/g) 0.35 (0.12–0.43) 0.10 (0–0.43) 0.0003
Lyso-Gb3 (nmol/L) 3.10 (2.9–6.4) 7.25 (3.2–12.0) NS
Time on therapy (months) 96 (15–168) 48 (13–180) NS

Data are presented as median (range) unless otherwise indicated.

NS, non-significant.